A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants Article

Full Text via DOI: 10.1186/s12871-021-01477-5 Web of Science: 000712211900001
Open Access Industry Collaboration International Collaboration

Cited authors

  • Herring WJ, Mukai Y, Wang AB, Lutkiewicz J, Lombard JF, Lin L, Watkins M, Broussard DM, Blobner M

Abstract

  • Background: The aim of this randomized, double-blind trial was to evaluate the safety and tolerability profile, including cardiac safety, of sugammadex-mediated recovery from neuromuscular block in participants undergoing surgery who met the American Society of Anesthesiologists (ASA) Physical Class 3 or 4 criteria. Specifically, this study assessed the impact of sugammadex on cardiac adverse events (AEs) and other prespecified AEs of clinical interest.Methods: Participants meeting ASA Class 3 and 4 criteria were stratified by ASA Class and NMBA (rocuronium or vecuronium) then randomized to one of the following: 1) Moderate neuromuscular block, sugammadex 2 mg/kg; 2) Moderate neuromuscular block, neostigmine and glycopyrrolate (neostigmine/glycopyrrolate); 3) Deep neuromuscular block, sugammadex 4 mg/kg; 4) Deep neuromuscular block, sugammadex 16 mg/kg (rocuronium only). Primary endpoints included incidences of treatment-emergent (TE) sinus bradycardia,TE sinus tachycardia and other TE cardiac arrhythmias.Results: Of 344 participants randomized, 331 received treatment (61% male, BMI 28.5 +/- 5.3 kg/m(2), age 69 +/- 11 years). Incidence of TE sinus bradycardia was significantly lower in the sugammadex 2 mg/kg group vs neostigmine/glycopyrrolate. The incidence ofTE sinus tachycardia was significantly lower in the sugammadex 2 and 4 mg/kg groups vs neostigmine/glycopyrrolate. No significant differences in other TE cardiac arrythmias were seen between sugammadex groups and neostigmine/glycopyrrolate. There were no cases of adjudicated anaphylaxis or hypersensitivity reactions in this study.Conclusions: Compared with neostigmine/glycopyrrolate, incidence of TE sinus bradycardia was significantly lower with sugammadex 2 mg/kg and incidence of TE sinus tachycardia was significantly lower with sugammadex 2 mg/ kg and 4 mg/kg. These results support the safety of sugammadex for reversing rocuronium- or vecuronium-induced moderate and deep neuromuscular block in ASA Class 3 or 4 participants.

Authors

Publication date

  • 2021

Published in

Category

International Standard Serial Number (ISSN)

  • 1471-2253

Number of pages

  • 11

Volume

  • 21

Issue

  • 1